BioXcel Therapeutics Inc (BTAI)
2.01
-0.08
(-3.83%)
USD |
NASDAQ |
May 20, 15:06
BioXcel Therapeutics Enterprise Value: 105.18M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 105.18M |
| May 16, 2024 | 105.93M |
| May 15, 2024 | 104.81M |
| May 14, 2024 | 107.43M |
| May 13, 2024 | 109.50M |
| May 10, 2024 | 105.93M |
| May 09, 2024 | 114.00M |
| May 08, 2024 | 107.06M |
| May 07, 2024 | 115.69M |
| May 06, 2024 | 120.45M |
| May 03, 2024 | 122.67M |
| May 02, 2024 | 122.30M |
| May 01, 2024 | 121.56M |
| April 30, 2024 | 120.82M |
| April 29, 2024 | 123.04M |
| April 26, 2024 | 124.89M |
| April 25, 2024 | 124.15M |
| April 24, 2024 | 127.86M |
| April 23, 2024 | 137.48M |
| April 22, 2024 | 133.04M |
| April 19, 2024 | 129.34M |
| April 18, 2024 | 121.93M |
| April 17, 2024 | 123.41M |
| April 16, 2024 | 126.74M |
| April 15, 2024 | 129.34M |
| Date | Value |
|---|---|
| April 12, 2024 | 134.89M |
| April 11, 2024 | 130.82M |
| April 10, 2024 | 124.89M |
| April 09, 2024 | 113.93M |
| April 08, 2024 | 115.94M |
| April 05, 2024 | 116.95M |
| April 04, 2024 | 117.96M |
| April 03, 2024 | 116.28M |
| April 02, 2024 | 116.28M |
| April 01, 2024 | 122.33M |
| March 31, 2024 | 122.33M |
| March 28, 2024 | 130.22M |
| March 27, 2024 | 132.24M |
| March 26, 2024 | 122.83M |
| March 25, 2024 | 122.52M |
| March 22, 2024 | 121.30M |
| March 21, 2024 | 121.91M |
| March 20, 2024 | 120.38M |
| March 19, 2024 | 118.55M |
| March 18, 2024 | 119.16M |
| March 15, 2024 | 116.80M |
| March 14, 2024 | 122.57M |
| March 13, 2024 | 122.57M |
| March 12, 2024 | 119.53M |
| March 11, 2024 | 123.48M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
32.79M
Minimum
Nov 07 2019
1.364B
Maximum
Feb 11 2021
427.83M
Average
323.79M
Median
Mar 17 2020
Enterprise Value Benchmarks
| Cormedix Inc | 222.84M |
| Amicus Therapeutics Inc | 2.983B |
| Insmed Inc | 4.248B |
| Altimmune Inc | 385.90M |
| InfuSystems Holdings Inc | 166.25M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -26.79M |
| Revenue (Quarterly) | 0.582M |
| Total Expenses (Quarterly) | 24.74M |
| EPS Diluted (Quarterly) | -0.87 |
| Gross Profit Margin (Quarterly) | 86.25% |
| Profit Margin (Quarterly) | -4.60K% |
| Earnings Yield | -257.2% |
| Normalized Earnings Yield | -250.14 |